Entrectinib belongs to which generation of targeted drugs and its clinical advantages

Entrectinib is a new generation of multi-target tyrosine kinase inhibitors that mainly targets NTRK fusion protein, ROS1 and ALK gene abnormalities. It is classified as a "new generation" or third-generation targeted drug due to its broader target coverage and superior brain metastasis penetration. The emergence of entrectinib provides new treatment hope for patients with multiple gene fusion-driven tumors, especially those with central nervous system metastasis.

Compared with first- and second-generation targeted drugs, entrectinib shows significant clinical advantages. First, it can effectively penetrate the blood-brain barrier and provide effective control for patients with brain metastases, which is rare among many traditional targeted drugs. Brain metastases are a significant challenge for many patients with advanced lung cancer and other solid tumors, and this ability of entrectinib makes it an ideal choice for patients with brain metastases.

Second, entrectinib has shown high efficacy in treating NTRK fusion-positive tumors, with objective response rates (ORR) exceeding 70% regardless of tumor type. In addition, entrectinib also showed excellent efficacy and tolerability in patients with ROS1-positive non-small cell lung cancer, significantly prolonging progression-free survival (PFS) and improving patients' quality of life.

Finally, entrectinib has a good safety profile. Common side effects are mostly mild to moderate, such as fatigue, nausea, constipation and hematological abnormalities, and most of them can be controlled through symptomatic treatment or dose adjustment. In summary, entrectinib, as a third-generation multi-target drug, occupies an important position in the field of precision tumor treatment. It is especially suitable for gene fusion-positive patients with brain metastasis, reflecting the development trend of precision medicine.

Reference materials:https://www.drugs.com